Upadacitinib

AbbVie has announced topline results for the second of its two Phase 3 clinical trials evaluating upadacitinib (RINVOQ) for alopecia areata.  What is RINVOQ? The treatment is a prescription Janus kinase (JAK) inhibitor that is used to treat several conditions, like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. It is currently also being…